1-8 of 8
Daniel Hochhauser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Free
Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Joseph Chao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 1923–1931.
https://doi.org/10.1158/1078-0432.CCR-20-2980
Published: 01 April 2021
View articletitled, Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Open the PDF for Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 in another window
Journal Articles

Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography

Free
Hannah E. Greenwood, Patrick N. McCormick, Thibault Gendron, Matthias Glaser, Raul Pereira, Oliver D. K. Maddocks, Kerstin Sander, Tong Zhang, Norman Koglin, Mark F. Lythgoe, Erik Årstad, Daniel Hochhauser, Timothy H. Witney
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2471–2482.
https://doi.org/10.1158/1078-0432.CCR-18-3423
Published: 15 April 2019
View articletitled, Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography
Open the PDF for Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography in another window
Includes: Multimedia, Supplementary data
Journal Articles

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response

Free
Francesca Vena, John A. Hartley, Daniel Hochhauser
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2595.
https://doi.org/10.1158/1078-0432.CCR-16-0566
Published: 12 May 2016
View articletitled, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response
Open the PDF for The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response in another window
Journal Articles

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Free
Francesca Vena, Eleonora Li Causi, Manuel Rodriguez-Justo, Samantha Goodstal, Thorsten Hagemann, John A. Hartley, Daniel Hochhauser
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5563–5577.
https://doi.org/10.1158/1078-0432.CCR-15-0485
Published: 14 December 2015
View articletitled, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Open the PDF for The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1) in another window
Includes: Supplementary data
Journal Articles

Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage

Free
Gianmaria Liccardi, John A. Hartley, Daniel Hochhauser
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (13): 3496–3506.
https://doi.org/10.1158/1078-0432.CCR-13-2695
Published: 30 June 2014
View articletitled, Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Open the PDF for Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage in another window
Includes: Supplementary data
Journal Articles

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

Free
Jenny Wu, Peter H. Clingen, Victoria J. Spanswick, Maria Mellinas-Gomez, Tim Meyer, Igor Puzanov, Duncan Jodrell, Daniel Hochhauser, John A. Hartley
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 721–730.
https://doi.org/10.1158/1078-0432.CCR-12-2529
Published: 31 January 2013
View articletitled, γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
Open the PDF for γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000) in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

Free
Daniel Hochhauser, Timothy Meyer, Victoria J. Spanswick, Jenny Wu, Peter H. Clingen, Paul Loadman, Margaret Cobb, Lindsey Gumbrell, Richard H. Begent, John A. Hartley, Duncan Jodrell
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2140–2147.
https://doi.org/10.1158/1078-0432.CCR-08-1315
Published: 16 March 2009
View articletitled, Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors in another window
Journal Articles

Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839)

Free
Benjamin Friedmann, Martyn Caplin, John A. Hartley, Daniel Hochhauser
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6476–6486.
https://doi.org/10.1158/1078-0432.CCR-04-0586
Published: 08 October 2004
View articletitled, Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839)
Open the PDF for Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) in another window